Congress Begins
  • in 52 days
  • Scientific Program

    Download a PDF of the program here.

    Please check back later for further information. Please contact ish2018-speakers at icsevents.com for further information.

    ThursdaySeptember 13, 2018

    • 08:30 - 10:00

      Venous Thromboembolic Disease

      Location: East Ballroom A&B, East Building, Vancouver Convention Centre
      Chair(s):
      • HIT and DIC: Unraveling the Causes of Ischemic Limb Injury Dr. Ted Warkentin, Hamilton, Canada
      • Management of Cancer-Associated Thrombosis: Dr. Cynthia Wu, Edmonton, Canada
    • 10:30 - 12:00

      Plasma Cell Disorders - 1

      Location: East Ballroom A&B, East Building, Vancouver Convention Centre
      Chair(s):
      • Antibody Therapies in Multiple Myeloma: Dr. Kevin Song, Vancouver, Canada
      • Understanding the Genetic Changes in Myeloma: Dr. Brian Walker, Little Rock, AR, USA
      • Modern Management of AL-Amyloidosis: Dr. Christopher Venner, Edmonton, Canada
    • 13:30 - 15:00

      ISH-ASH Joint Symposium: Targeted Therapies in Hematology

      Location: East Ballroom A&B, East Building, Vancouver Convention Centre
      Chair(s):
      • Gene Inhibitor Therapy in AML: Dr. Donna Hogge, Vancouver, Canada
      • JAK inhibition in Chronic MPDs: Dr. Ruben Mesa, San Antonio, USA
      • CRISPR/Cas9 Genome Editing in Hemoglobinopathies: Dr. Fabien Touzot, Montreal, Canada
    • 15:15 - 16:15

      Plenary Abstracts

      Location: East Ballroom A&B, East Building, Vancouver Convention Centre
      Chair(s):
      • Safety, Efficacy and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients: Ulrich Jäger, Vienna, Austria
      • Clinical significance of ASXL2 and ZBTB7A mutations and AML1-ETO9a expression in AML with t(8;21): the JALSG AML201 study: Naomi Kawashima, Nagoya, Japan
      • Dose Finding Study of SC411 for the Treatment of Children with Sickle Cell Disease (SCOT Trial): Ahmed Daak, Alabama, USA
      • Gold medal for Best Abstract: Identification of CD248 as a novel cofactor for tissue factor (TF) activation of coagulation: Piyushkumar Kapopara, Vancouver, Canada
    • 16:15 - 17:15

      Special Session: Case Presentations

      Location: East Ballroom A&B, East Building, Vancouver Convention Centre
      Chair(s): Drs. Thomas Nevill & Monika Hudoba , Canada
      • Case Presentations: Dr. Thomas Nevill and Dr. Monika Hudoba, Vancouver, Canada
    • 17:15 - 17:45

      Opening Ceremony

      Location: East Ballroom A&B, East Building, Vancouver Convention Centre
      Chair(s):

    FridaySeptember 14, 2018

    • 08:30 - 10:00

      Acute Myelogenous Leukemia

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Prognostic Stratification in AML: Dr. Roland Walter, Seattle, USA
      • Germline Mutations Associated With Myeloid Neoplasms: Dr. Carolyn Owen, Edmonton, Canada
      • Determining the Optimal Treatment for Patients with AML: Dr. Andre Schuh, Toronto, Canada
    • 08:30 - 10:00

      Acquired Coagulopathies

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Treatment of Acquired Hemophilia A: Dr. Rebecca Kruse-Jarres, Seattle, USA
      • Managing the Hemostatic Defects of Massive Transfusion Syndrome: Dr. Andrew Shih, Vancouver, Canada
      • Controlling Hemorrhage in a Patient with Liver Disease: Dr. Jody Kujovich, Portland, SA
    • 08:30 - 10:00

      Developments in Apheresis

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • One of the TMAs: Current Approaches and Management of Thrombotic Thrombocytopenic Purpura: Dr. Gail Rock, Ottawa, Canada
      • Stem Cell Mobilization Strategies: Dr. Gayatri Sreenivasan, Vancouver, Canada
      • Extracorporeal Photopheresis for Treatment of Graft-versus-Host Disease: Dr. Raewyn Broady, Vancouver, Canada
    • 08:30 - 10:00

      Leukocytes, Inflammation, Infections and Immunology

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • Etoposide-based treatment of adult HLH is associated with high biochemical response but poor survival outcomes: Matthew Nicholson, Vancouver, Canada
      • Contribution of Dengue Virus Nonstructural Protein 1 to Platelet Activation and Thrombocytopenia in Hemorrhagic Mice Model: Chiao-Hsuan Chao, Tainan, Taiwan
      • The GBA p.W378G mutation is a founder French-Canadian mutation causing Gaucher disease and synucleinopathies: Dominick Amato, Toronto, Canada
      • Neutrophil Side Scatter (NEUT-SSC)- An indicator of Immune dysfunction in Chronic Kidney Disease?: Roshini Shekhar, Bengaluru, India
      • Atypical Lymphocyte Count Correlates with Severity of Thrombocytopaenia in Dengue Infection: Visula Abeysuriya, Colombo, Sri Lanka
    • 08:30 - 10:00

      Plasma Cell Dyscrasias

      Location: East Meeting Room 19, East Building, Vancouver Convention Centre
      Chair(s):
      • Interference of Laboratory Tests by M-proteins in Patients with Hematologic Malignancy: A Systematic Review: Ronan Hsieh, Rochester, USA
      • Rituximab in Idiopathic Retroperitoneal Fibrosis: Veronika Boyeva, Vancouver, Canada
      • Prevalence of IgG4-Related Disease in Patients with Hypergammaglobinemia: Eric Zhao, Vancouver, Canada
      • The Real World Impact of Lenalidomide Maintenance After Autologous SCT and Bortezomib-Based Induction in Multiple Myeloma: Hannah Cherniawsky, Edmonton, Canada
      • Cardiovascular Mortality Trends in Multiple Myeloma: a Population-Based Cohort Study: Muhammed Elfaituri, Tripoli, Libya
      • Diagnostic performance of the quantification of free immunoglobulin light chains for the detection of multiple myeloma: Guillermo J. Ruiz-Argüelles, Puebla, Mexico
    • 10:30 - 12:00

      Stem Cell and Telomere Biology

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • What We Know about AML Stem Cells: Dr. Donna Hogge, Vacouver, Canada
      • Telomeres and Telomerase in Normal and Malignant Hematopoiesis: Dr. Peter Lansdorp, Vancouver, Canada
    • 10:30 - 12:00

      Inherited Bleeding Disorders

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Molecular Genetics of Von Willebrand’s Disease: Dr. David Lillicrap, Kingston, ON, Canada
      • Management of the Undefined Bleeding Disorder: Dr. Shannon Jackson, Vancouver, Canada
      • Antibody Therapy in Hemophilia: Dr. Guy Young, Los Angeles, USA
    • 10:30 - 12:00

      Aggressive Non Hodgkin Lymphoma

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Checkpoint Inhibitors in Lymphoma: Dr. Kerry Savage, Vancouver, Canada
      • The role of autologous stem cell transplantation in management of primary CNS lymphoma: Dr. Doug Stewart, Calgary, Canada
      • Management of Double and Triple-Hit Lymphomas: Dr. David Scott, Vancouver, Canada
    • 10:30 - 12:00

      Red Cell Physiology, Iron Metabolism and Disorders

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • Gestational perturbation of homocysteine metabolism: A possible basis for zero prevalence of Spina bifida in Osogbo, Nigeria: Emmanuel Akanni, Osogbo, Nigeria
      • Amlodipine with Chelation Therapy can Reduce Iron Overload in Thalassemia Major: Systematic Review and Meta-analysis: Muhammed Elfaituri, Tripoli, Libya
      • An alternative sickle cell disease severity scoring system in a resource-constrained setting – A Pilot Study: Aliyu Waziri, Zaria, Nigeria
      • Monthly Red Cell Exchange Treatment for a Patient with High Oxygen-Affinity Hemoglobin Johnstown/Hemoglobin Lepore: Chisa Yamada, Ann Arbor, USA
      • Effect of vitamin D and calcium Supplementation on Bone Mineral Content in Children with Thalassemia: C. G. Delhikumar, Puducherry, India
    • 10:30 - 12:00

      Acute Leukemia/Myelodysplastic Syndromes/Myeloproliferative Neoplasms

      Location: East Meeting Room 19, East Building, Vancouver Convention Centre
      Chair(s):
      • Stem Cells in Acute Lymphoblastic Leukemia and In-Vitro Assessment of the Effect of Parthenolide: Hessah Alsulami, Manamah, Bahrain
      • Survival Outcomes of Elderly Acute Myeloid Leukaemia (AML) Patients Treated in a British District General Hospital: Charles Agbuduwe, Peterborough, UK
      • Inhibiting mTOR signalling unlocks acute myeloid leukemia resistance to epigenetic drugs: Amal Kamal Abdel-Aziz, Milan, Italy
      • Crocetin induced differentiation and apoptosis in human acute promyelocytic leukemia cells: Maliheh Moradzadeh, Gorgan, Iran
      • Validation of a targeted next-generation DNA and RNA sequencing panel for myeloid neoplasms: Christina Ferrone, Kingston, Canada
    • 13:30 - 15:00

      Chronic Lymphocytic Leukemia

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Pathogenesis & Risk Factors for CLL: Dr. Cynthia Toze, Vancouver, Canada
      • Which therapy is Best for del(17p) CLL: Ibrutinib or Ventoclax: Dr. Alina Gerrie, Vancouver, Canada
      • Where Does Allogeneic Transplantation Fit in the Management of CLL?: Dr. Cynthia Toze, Vancouver, Canada
    • 13:30 - 15:00

      Advances in the Treatment of Hemoglobinopathies

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Hydroxyurea, Transfusions & Supportive Care in Sickle Cell Anemia: Dr. Nancy Robitaille, Montreal, Canada
      • Allogeneic Stem Cell Transplantation in Hemoglobinopathies: Dr. Christina Peters, Vienna, Austria
      • New Therapies in ß Thalassemia: Dr. Richard Ward, Toronto, Canada
    • 13:30 - 15:00

      Benign Cytopenias

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Controversies in the Management of ITP: Dr. Adrian Newland, London, UK
      • Clonal Hematopoiesis in Congenital Neutropenia/G-CSF in Cyclic Neutropenia Dr. David Dale, Seattle, USA
    • 15:30 - 17:00

      Hodgkin Lymphoma

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Will Brentuximab Vedotin & Nivolumab Improve Survival in Relapsed/Refractory Hodgkin Lymphoma?: Dr. Alina Gerrie, Vancouver, Canada
      • Treatment of Grey Zone Lymphomas: Dr. Joseph Connors, Vancouver, Canada
      • Is There a Role for Allogeneic Stem Cell Transplantation in Hodgkin Lymphoma?: Dr. John Kuruvilla, Toronto, Canada
    • 15:30 - 17:00

      Chronic Myeloid Leukemia

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Choosing the Best Frontline Therapy in Chronic Myeloid Leukemia: Dr. Jeff Lipton, Toronto, Canada
      • Molecular Mechanisms in CML: From Transformation to TKI Discontinuation: Dr. Pierre Laneuville, Montreal, Canada
      • When is it Safe to Discontinue TKIs?: Dr. Donna Forrest, Vancouver, Canada
    • 15:30 - 17:00

      Eosinophils, Mast cells & Histiocytes

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • New Insights into the Molecular Genetics of Non-Langerhans Histiocytosis: Dr. Julien Haroche, Paris, France
      • Management of Mast cell Disease: Indolent, Smoldering & Aggressive: Dr. Animesh Pardanani, Rochester, USA
      • Eosinophilic diseases: Dr. Luke Chen, Vancouver, Canada
    • 17:00 - 18:00

      Special Hematology Session: Nuclear Terrorism

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s): Dr. Robert P. Gale, UCLA/UK
      • Nuclear Terrorism: Dr. Robert Gale, Los Angeles, USA
    • 17:00 - 18:00

      Meet-the-Expert Session

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Treatment of Post-Autograft Relapse of Hodgkin Lymphoma: Dr. Joseph Connors, Vancouver, Canada
    • 17:00 - 18:00

      Meet-the-Expert Session

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Heparin-induced thrombocytopenia (HIT): Dr. Ted Warkentin, Hamilton, Canada

    SaturdaySeptember 15, 2018

    • 08:30 - 10:00

      Advances in Allogeneic Stem Cell Transplantation

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Post-transplantation Cyclophosphamide in Unrelated Donor SCT: Dr. Marco Mielcarek, Seattle, USA
      • Is Haploidentical Transplantation the Way of the Future?: Dr. Robert Gale, Los Angeles, USA
    • 08:30 - 10:00

      Obstetric Hematology

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Treatment of Lymphoma in Pregnancy: Dr. Joseph Connors, Vancouver, Canada
      • Management of Thrombocytopenia in Pregnancy: Dr. Leslie Zypchen, Vancouver, Canada
      • Navigating Pregnancy in a Woman Who has An Inherited Bleeding Disorder: Dr. Shannon Jackson, Vancouver, Canada
    • 08:30 - 10:00

      Transfusion Medicine

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Transfusion Outcomes after Short and Long-term Blood Storage: Dr. Ted Warkentin, Hamilton, Canada
      • Thresholds for Red Cell and Platelet Transfusions in Acute Leukemia Patients: Dr. Andrew Shih, Vancouver, Canada
      • Transfusion-Related Acute Lung Injury: Risk factors, Management & Prevention: Dr. Tanya Petraszko, Vancouver, Canada
    • 10:30 - 12:00

      Red Cell Disorders

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Management of Pure Red Cell Aplasia: Dr. Robert Means, Johnson City, TN, USA
      • Megaloblastic Anemias: Why Are They Still Important?: Dr. Ralph Green, Sacramento, USA
      • A Practical Approach to Hyperferritinemia: Dr. Luke Chen, Vancouver, Canada
    • 10:30 - 12:00

      Indolent Lymphoproliferative Disorders

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Novel Therapies for Follicular Lymphoma: Dr. Laurie Sehn, Vancouver, Canada
      • Can We Agree on Optimal Management of Mantle Cell Lymphoma: Dr. John Kuruvilla, Toronto, Canada
      • BRAF Inhibitors in Hairy Cell Leukemia: Dr. Michael Grever, Columbus, USA
    • 10:30 - 12:00

      Acute Lymphoblastic Leukemia

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • New Insights into the Genetics of Childhood ALL: Dr. Kirk Schultz, Vancouver, Canada
      • CAR T-cell therapy in ALL: Dr. Shannon Maude, Philadelphia, USA
    • 10:30 - 12:00

      Transfusion Medicine & Apheresis

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • Can We Transfuse Wisely in Patients Undergoing Chemotherapy for Acute Leukemia or Autologous Stem Cell Transplantation?: Danielle Hammond, Kingston, Canada
      • The coagulability of platelets can be increased by loading them with liposomal thrombin: Christian Kastrup, Vancouver, Canada
      • Inappropriate use of fresh frozen plasma in a tertiary care hospital: Sidra Ali, Karachi, Pakistan
      • Forty years of apheresis in Canada: Gail Rock, Ottawa, Canada
      • Factors influencing platelet refractoriness in hematology-oncology patients — a retrospective analysis of 52 cases: Elisabeth Maurer-Spurej, Vancouver, Canada
      • Blood Donor Deferrals in Tertiary Hospital Blood Bank from January to December 2016: Madonna Ancheta, Manila, Philippines
    • 10:30 - 12:00

      Gene Therapy, Immunotherapy, Transplantation and Experimental Therapeutics

      Location: East Meeting Room 19, East Building, Vancouver Convention Centre
      Chair(s):
      • Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: The Ottawa Experience: Shona Philip, Ottawa, Canada
      • Relapse-free survival after hematopoietic stem cell transplants in multiple sclerosis using the “Mexican Method”: Guillermo J. Ruiz-Argüelles, Puebla, Mexico
      • TAS4464, NEDD8 activating enzyme inhibitor, induces apoptosis for Primary effusion lymphoma cells: Seiji Okada, Kumamoto, Japan
      • SLAMF-7 (CD319): a potential new therapeutic target for the treatment of primary effusion lymphoma: Jutatip Panaampon, Kumamoto, Japan
      • Acute Graft-Versus-Host Disease (aGVHD) Treatment Outcomes in Adult Stem Cell Transplants (SCT) in British Columbia 2001-2016: Mara Westendorp, Vancouver, Canada
      • Variability of contribution of 1,25 (OH)2D3 (vitamin D) level to hematopoietic stem cell transplantation outcome: Azza Kamel, Cairo, Egypt
    • 13:30 - 15:00

      Plasma Cell Disorders - 2

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Developing a Rational Approach to the Treatment of Multiple Myeloma: Dr. Joseph Mikhael, North Hollywood, USA
      • Overview of IgG-4 Disease: Dr. Mollie Carruthers, Vancouver, Canada
      • Monoclonal Gammopathy with Renal Significance: Dr. Joseph Mikhael, North Hollywood, USA
    • 13:30 - 15:00

      Bone Marrow Failure

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • GATA2 Mutation Disorders/Telomeropathies: Dr. Thomas Nevill, Vancouver, Canada
      • Treatment of Large Granular Lymphocyte Leukemia: Dr. Thomas Loughran, Charlottesville, USA
      • Etiology, Pathogenesis & Initial Therapy of Aplastic Anemia: Dr. Phillip Scheinberg, Sao Paulo, Brazil
    • 13:30 - 15:00

      Hematology in the Developing World

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Improving the Outcomes for Leukemia & Lymphoma in Developing Countries: Dr. David Gomez Almaguer, Monterrey, Mexico
      • Helminthic Disease of the Lungs in Immunocompromised Patients: Dr. Alissa Wright, Vancouver, Canada
      • Systematic Analysis of Global Anemia & Global Epidemiology of Hemglobinopathies: Dr. Nicholas Kassebaum, Seattle, USA
    • 15:30 - 17:00

      Myelodysplastic Syndromes

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • The Role of Next Generation Sequencing in Prognosis: Dr. Rafael Bejar, San Diego, USA
      • Novel Therapies in Low and High-Risk MDS: Dr. Mikkael Sekeres, Cleveland, Canada
      • Management of Iron Overload in MDS: Dr. Heather Leitch, Vancouver, Canada
    • 15:30 - 17:00

      Laboratory Hematology

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Laboratory Investigation of Disorders of Platelet Function: Dr. Catherine Hayward, Hamilton, Canada
      • MRD Testing by Flow Cytometry in Acute Myeloid Leukemia: Dr. Roland Walter, Seattle, USA
      • Hemoglobinopathies - Current Screening and Diagnostic Practices: Dr. Nicholas Au, Vancouver, Canada
    • 15:30 - 17:00

      Congenital Disorders With Hematologic Significance

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Diagnosis and Management of Gaucher Disease: Dominick Amato, Toronto, Canada
      • Familial Hemophagocytic Lymphohistiocytosis: David Dix, Vancouver, Canada
      • Fanconi Anemia: Genetics and Clinical Implications: Dr. Sule Unal, Ankara, Turkey
    • 15:30 - 17:00

      Chronic Leukemias/Hodgkin and Non-Hodgkin Lymphomas

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • A modified CLL International Prognostic Index (CLL-LIPI) replacing IgHV mutation status with lymphocyte doubling time (LDT): Deepesh Lad, Chandigarh, India
      • Late Cardiac Side Effects In Chronic Myeloid Leukemia (CML) Patients on Long-term Tyrosine Kinase Inhibitor (TKI) Therapy: Leanne Genge, Vancouver, Canada
      • Metformin plus R-CHOP in patients with diffuse large B-cell lymphoma: a phase I/II study: Andrés Gómez-De León, Monterrey, Mexico
      • Clinical correlation between translocation variant and outcome in Philadelphia chromosome-positive chronic myeloid leukemia: Zeeshan Ahmed, Karachi, Pakistan
      • Hodgkin Lymphoma in Resource Limited Setting: A Two Center Experience in Malaysia: Tze Shin Leong, Ampang Selangor, Malysia
      • Diffuse large B cell lymphoma in adolescents and young adults; clinical characteristics and outcomes: Yasuhiro Suzuki, Nagoya, Japan
    • 15:30 - 17:00

      Hemostasis, Thrombosis and Vascular Wall Biology

      Location: East Meeting Room 19, East Building, Vancouver Convention Centre
      Chair(s):
      • Age-Adjusted D-Dimer Cut-off Level for Venous Thromboembolism Exclusion. Clinical Performance and Cost-Effectiveness Analysis: Pierre Toulon, Nice, France
      • Pediatric Thrombotic Events: Incidence, Clinical Risk Factors, and Outcome: C.G. Delhikumar, Puducherry, India
      • The impact of age on the pharmacological activity of rivaroxaban: Emmanouela Kampouraki, Newcastle, UK
      • Evaluation of bleeding profile and quality of life parameters in patients of Hemophilia on factor prophylaxis: Manoranjan Mahapatra, New Delhi, India
      • Influence of non-platelet parameters on platelet counts in automated blood cell counters: Ganesh Kumar Viswanathan, Bangalore, India
      • Coagulation Factor XIIIa is Inactivated During Thrombolytic Treatment: Woosuk Hur, Vancouver, Canada
    • 17:00 - 18:00

      Meet-the-Expert

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Deciding on Post-Transplant Maintenance in Multiple Myeloma: Dr. Joseph Mikhael, North Hollywood, USA
    • 17:00 - 18:00

      Morphology Session

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • Sample Cases of Newly Defined Entities in the WHO 2016 Classification of Hematological Malignancies: Dr Aysegul Uner, Ankara, Turkey
    • 17:00 - 18:00

      Meet-the-Expert

      Location: East Meeting Room 19, East Building, Vancouver Convention Centre
      Chair(s):
      • Management of Aplastic Anemia Unresponsive to Cyclosporine/ATGAM: Dr. Phillip Scheinberg, Sao Paulo, Brazil

    SundaySeptember 16, 2018

    • 07:30 - 08:30

      Meet-the-Expert Session

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • The Problematic ITP Patient- Current management and future treatment options: Dr. Adrian Newland, London, UK
    • 07:30 - 08:30

      Meet-the-Expert Session

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • Treatment of MDS with a High-risk Molecular Profile: Dr. Mikkael Sekeres, Cleveland, USA
    • 08:30 - 10:00

      Complement Disorders

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • New Genetic Insights and Evolving Therapies for Paroxysmal Nocturnal Hemoglobinuria: Dr. Christopher Patriquin, Toronto, Canada
      • Diagnosis and Management of Atypical Hemolytic Uremic Syndrome: Dr. Gayatri Sreenivasan, Vancouver, Canada
      • Complement Activation in Anti-Phospholipid antibody Syndrome: Dr. Christopher Patriquin, Toronto, Canada
    • 08:30 - 10:00

      Myeloproliferative Disorders

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Polycythemia Vera: Approach to Treatment: Dr. Lynda Foltz, Vancouver, Canada
      • Prognostic Factors in Myelofibrosis and Essential Thrombocytosis: Ruben Mesa, San Antonio, USA
    • 08:30 - 10:00

      Organizing a BMT Unit in Underpriveleged Circumstances

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • General Guidelines: Dr. Robert Gale, Los Angeles, USA
      • Experience in Turkey: Dr. Emin Kansu, Ankara, Turkey
      • Organizing a BMT Unit in Underprivileged Circumstances: Dr. Guillermo Ruiz-Arguelles, Puebla, Mexico
    • 08:30 - 10:00

      Hematopoiesis, Stem Cells, Non-malignant Hematopoietic Diseases & Marrow Failure

      Location: East Meeting Room 18, East Building, Vancouver Convention Centre
      Chair(s):
      • Outcome of Stem cell transplant of 100 Aplastic Anemia patients: A Single Centre Experience from India: Manoranjan Mahapatra, New Delhi, India
      • Extrinsic Glycosylation by ST6Gal-1 is a Positive Regulator of Transitional B Cell Development: Eric Irons, Buffalo, USA
      • Disorders with GPI-deficient Blood Cells: Outcomes with Eculizumab, Immunosuppression (IST) and Marrow Transplantation (BMT): Jillian Speakman, Vancouver, Canada
      • Eltrombopag Treatment Improved Platelet Counts in Persistent and Chronic ITP Patients: A 2-Year, Phase 4, Open-label Study: Raymond Wong, Hong Kong, China
      • Clinico-etiological Profile and Outcome of Pancytopenia with Prolonged fever – Prospective Study from northern India: PL Vidya, New Delhi, India
      • Assessment of Knowledge, Attitude & Practices Related to Thalassemia Among Interns and Residents in Pakistan: Umera Saleem, Karachi, Pakistan
    • 08:30 - 10:00

      Health Services and Outcomes Research

      Location: East Meeting Room 19, East Building, Vancouver Convention Centre
      Chair(s):
      • Examining molecular response and quality of life in chronic phase chronic myeloid leukemia in the Bosutinib BFORE trial: Tim Brummendorf, Aachen, Germany
      • Real-world health-related quality of life data from haemophilia patients in France and the UK: Jérémy Lambert, Lyon, France
      • Real-world health utility scores from haemophilia patients in France and the UK: Jérémy Lambert, Lyon, France
      • Outpatient hematology visits as a measure of disease burden: insights from a university hospital in Mexico: Andrés Gómez-De León, Monterrey, Mexico
      • Burden of illness among patients with severe aplastic anemia and an insufficient response to immunosuppressive therapy: Anuja Roy, New Jersey, USA
      • Blood Donation Practice and its Associated Factors Among Health Professionals in Addis Ababa, Ethiopia: Yakob Tsegay, Addis Ababa, Ethiopia
    • 10:30 - 12:00

      Disorders of Platelet Number and Function

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s):
      • Use of Genomics to Uncover Novel Inherited Platelet Disorders: Dr. Jacob Rozmus, Vancouver, Canada
      • Causes and Consequences of Constitutional Platelet Dysfunction: Dr. Catherine Hayward, Hamilton, Canada
    • 10:30 - 12:00

      Autologous Stem Cell Transplantation

      Location: East Ballroom B, East Building, Vancouver Convention Centre
      Chair(s):
      • Autologous SCT for Multiple Sclerosis: Dr. Natasha Kekre, Ottawa, Canada
      • Cell Dose Thresholds for Autologous SCT: Dr. Maryse Power, Vancouver, Canada
    • 10:30 - 12:00

      Acute Lymphoblastic Leukemia - 2

      Location: East Meeting Room 1-3 & South Foyer, East Building, Vancouver Convention Centre
      Chair(s):
      • Antibody Therapies in ALL: Dr. Elias Jabbour, Houston, USA
      • Pediatric Protocols for the Treatment of Adult ALL: Dr. Yasser Abou Mourad, Vancouver, Canada
    • 12:00 - 12:45

      Closing Session: Key Take-Home Messages

      Location: East Ballroom A, East Building, Vancouver Convention Centre
      Chair(s): Dr. Thomas Nevill & Dr. Gail Rock , Canada
      • Key Take-Home Messages: Dr. Gail Rock, Ottawa, Canada and Dr. Thomas Nevill, Vancouver, Canada